Palatin (PTN) Q1 2027 Earnings Call Transcript

Source Motley_fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Tue, Nov. 17, 2026

CALL PARTICIPANTS

  • President and Chief Executive Officer - Dr. Carl Spana
  • Chief Financial Officer and Chief Operating Officer - Steve Wills

TAKEAWAYS

  • Revenue -- $362,000, representing research and development services performed under the collaboration with Boehringer Ingelheim.
  • R&D Expenses -- $3.4 million, compared with $2.5 million in the prior year period.
  • MC4R Obesity Program Spending -- $2.1 million, reflecting an increase from $1 million in the prior year period to advance IND-enabling studies.
  • Net Loss -- $5.1 million, or $1.29 per basic and diluted common share.
  • Cash and Equivalents -- $3.7 million, as of Sept. 30, 2026.
  • Net Cash Used in Operating Activities -- $3.7 million, compared with $1.6 million in the prior year period.
  • Prior Year Revenue -- $8.8 million, which included substantial upfront milestone payments from the Boehringer Ingelheim agreement.
  • Phase I Initiation Target -- first half of calendar 2027, for the lead lipidated MC4R peptide candidate.
  • Clinical Data Target -- second half of calendar 2027, for the planned Phase I study of the lipidated peptide.
  • Oral Small Molecule Phase I Target -- second half of calendar 2027, following candidate selection and IND-enabling development.
  • Oral Small Molecule Data Target -- first half of calendar 2028, tracking approximately two quarters behind the injectable peptide program.
  • G&A Expenses -- $2.1 million, compared with $1.7 million in the prior year period due to higher stock-based compensation and professional fees.
  • Total Employee Count -- 25, operating within the biotechnology sector.
  • Market Capitalization -- $10.91 million, as of the current reporting period.
  • Recent Collaboration Funding -- approximately $10 million, received from Boehringer Ingelheim since August 2025.
  • Stock Price -- $6.12, as reported for the Nasdaq-listed biotechnology firm.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Wills warned that advancing development programs through the next stages of clinical development will require additional capital, noting the company had $3.7 million in cash and equivalents as of Sept. 30, 2026.
  • Wills stated, "we cannot provide assurances regarding the timing or the terms of the transaction," in reference to evaluating financing alternatives to support development objectives.

SUMMARY

Palatin (NASDAQ:PTN) reported financial results for the fiscal first quarter ended Sept. 30, 2026, while management stated the company is progressing toward clinical milestones for its next-generation melanocortin-4 receptor (MC4R) obesity programs. The company reported that research and development investments are concentrated on its lead lipidated peptide and oral small molecule candidates. Management indicated that internal resources are prioritized for high-value clinical opportunities while other assets are advanced through strategic collaborations. The company stated that it is currently conducting IND-enabling and manufacturing activities to support the initiation of human clinical evaluation during calendar 2027.

  • CEO Spana stated, "activation of the melanocortin-1 receptor can cause skin darkening or hyperpigmentation, which has emerged as a challenge in the development of MCR4-based agonist therapeutics."
  • Spana noted that the PL2000 peptide candidate demonstrated significant reductions in food intake and body weight in diet-induced obese mice following once-weekly subcutaneous administration.
  • Management indicated that the lead lipidated peptide candidate supports the potential for once-weekly or even less frequent dosing in humans based on animal pharmacokinetic findings.
  • CFO Wills indicated that the increase in research and development spending was directly related to IND-enabling activities and lead candidate optimization for next-generation MC4R programs.
  • Management stated that the Altanispac Labs licensing arrangement for PL9643 transfers development responsibility while preserving potential future economics for the company.
  • Spana indicated that the oral peptide agonist approach has demonstrated gastrointestinal stability and oral bioavailability in preclinical evaluations.

INDUSTRY GLOSSARY

  • MC4R: Melanocortin-4 receptor, a protein primarily associated with the regulation of appetite, food intake, and energy balance.
  • MCR1: Melanocortin-1 receptor, a protein involved in skin pigmentation; activation can lead to hyperpigmentation.
  • Lipidation: A chemical modification that attaches a lipid chain to a peptide to extend its duration of action and half-life in the body.
  • IND-enabling: Preclinical studies and manufacturing activities required before an Investigational New Drug application can be filed for human clinical trials.
  • SAD/MAD: Single Ascending Dose and Multiple Ascending Dose studies, which are initial clinical trials designed to assess safety, tolerability, and pharmacokinetics.

Full Conference Call Transcript

Operator: Hello, everyone. Welcome to Palatin's First Quarter Fiscal Year 2027 Operating Results Conference Call. As a reminder, this conference call is being recorded. Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove accurate and that actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatin's prospects. Now I would like to turn the call over to your host, Dr.

Carl Spana, President and Chief Executive Officer of Palatin. Please go ahead.

Carl Spana: Good morning, and welcome to Palatin's Fiscal First Quarter 2027 Call. I am Dr. Carl Spana, CEO and President of Palatin. With me on the call today is Steve Wills, Palatin's Chief Financial Officer and Chief Operating Officer. Steve will lead off the call with the financial and corporate update. Steve?

Steve Wills: Thank you, Carl, and good morning, everyone. I'll review our financial results for the fiscal 2027 first quarter ended September 30, 2026, and discuss our operating priorities and provide some perspective on our financial strategy as we move toward important clinical development milestones. During the quarter, we continued to focus our resources on advancing our next-generation MC4R programs, particularly the IND-enabling activities for our lead lipidated peptide and the development of our oral small-molecule candidates. We believe these investments are positioning Palatin for an important period of clinical development beginning in calendar year 2027.

Regarding fiscal first quarter financial results for the 3 months ended September 30, 2026, Palatin recognized approximately $362,000 in collaboration and license revenue compared with approximately $8.8 million for the comparable prior year period. Current quarter revenue was attributable to research and development services performed under our collaboration with Boehringer Ingelheim. The prior year period included substantial upfront milestone payments associated with that agreement, which accounts for the year-over-year difference. Turning to expenses. Research and development were approximately $3.4 million compared with approximately $2.5 million in the comparable prior year period. Importantly, spending directly related to our MC4R obesity development programs increased to approximately $2.1 million compared with approximately $1 million in the prior year period.

This increase reflects our continued advancement of IND-enabling studies and related development activities for our long-acting peptide program as well as lead candidate optimization activities for our oral small molecule program. We believe these expenditures represent important investments in advancing our development candidates toward clinical evaluation. General and administrative expenses were approximately $2.1 million compared with approximately $1.7 million in the comparable prior year period. The increase was primarily attributable to higher stock-based compensation expense and professional fees. For the fiscal first quarter, we reported a net loss of approximately $5.1 million or $1.29 per basic and diluted common share. Regarding Palatin's cash position and financial strategy.

Net cash used in operating activities was approximately $3.7 million during the quarter compared with approximately $1.6 million in the prior year period. As of September 30, 2026, we had approximately $3.7 million in cash and cash equivalents. We recognize that advancing our development programs through the next stages of clinical development will require additional capital. We are evaluating financing alternatives, including public and private equity transactions while continuing to pursue strategic collaborations and other opportunities to support our programs. Our financing strategy is directed toward obtaining the capital necessary to execute our development plans and achieve the milestones that we believe can create substantial value for Palatin and its shareholders.

We have successfully accessed the capital markets and executed strategic transactions throughout Palatin's history, and we remain focused on pursuing the financial resources required to advance our programs. At the same time, we continue to carefully manage operating expenditures and prioritize investment in our highest value development opportunities. Regarding strategic partnerships and operating priorities, an important component of our strategy is utilizing our broader melanocortin portfolio to create additional opportunities for value through licensing and collaboration agreements. Our partnership with Boehringer Ingelheim and our licensing arrangement with Altanispac Labs provide opportunities for future economic participation while allowing us to concentrate our internal resources on our MC4R obesity programs.

We also continue to evaluate strategic opportunities for our other development assets in the MC1R landscape. Looking ahead, our operating priorities remain clear. First, advance our lead lipidated MC4R peptide candidate through the necessary IND-enabling and manufacturing activities toward initiation of a Phase I clinical study in the first half of calendar year 2027. Second, progress our oral small molecule MC4R program toward candidate selection, IND-enabling development and planned clinical initiation in the second half of calendar year 2027. Third, continue expanding the opportunities within our MC4R portfolio, including our non-lipidated peptide series and oral peptide approach. And fourth, secure the financial and strategic resources necessary to support these objectives.

In closing, Palatin is entering an important period in its development. Our strategic direction is clearly established, our next-generation MC4R programs are advancing and our research and development investments are increasingly concentrated on programs with the potential for significant clinical and commercial differentiation. We believe Palatin has the scientific expertise, proprietary compounds and development capabilities to compete effectively in this emerging market. We remain confident in the potential of our programs and committed to advancing them through the next important stages of development. With that, I'll turn the call back to Carl. Carl?

Carl Spana: Thank you, Steve. Today, I want to focus on the significant opportunity we see for Palatin with our next-generation of melanocortin-4 receptor targeted therapies. The progress we are making across our development programs and the important milestones ahead. The treatment landscape for rare neuroendocrine obesity disorders continues to evolve rapidly. Importantly, melanocortin-4 receptor or MCR4 receptor agonism has now been clinically and commercially validated as a therapeutic approach for patients with certain rare obesity disorders driven by dysfunctions in the melanocortin pathway. This validation is important. It establishes that activating the MCR4 receptor can deliver meaningful clinical benefits in diseases that have historically been extremely difficult to treat.

This provides substantial opportunities for novel differentiated MCR4 therapeutics, which is where Palatin is focused. Our objective is to develop next-generation MCR4 agonist with the potential to deliver robust efficacy, substantially improved tolerability, minimal or no hyperpigmentation and dosing profiles that are practical for patients who may require treatment throughout their lives. We are applying our extensive knowledge of melanocortin receptor pharmacology, peptide engineering and drug development to create therapies designed to address the limitations of existing and emerging products. An important differentiating characteristic of our development programs is receptor selectivity. The melanocortin-4 receptor is the receptor principally associated with the regulation of appetite, food intake and energy balance, while the melanocortin-1 receptor is involved in skin pigmentation.

Activation of the melanocortin-1 receptor can cause skin darkening or hyperpigmentation, which has emerged as a challenge in the development of MCR4-based agonist therapeutics. For patients with rare obesity disorders who may require a lifelong treatment, minimizing these or this effect is important. Our strategy is to selectively activate the melanocortin-4 receptor while avoiding MCR1 activity. Tested compounds from our two next-generation peptide series have demonstrated potent melanocortin-4 receptor agonist activity without acting as agonists at the melanocortin-1 receptor. We believe this is a meaningful achievement and supports our objective of substantially reducing and potentially eliminating all MCR1-mediated hyperpigmentation.

Our goal is to develop MCR4 therapeutics with clinically meaningful efficacy without requiring patients to accept unnecessary adverse effects associated with off-target receptor activation. We believe this is going to be an important differentiating factor. Turning to our lead program. We continue to make progress advancing our lipidated long-acting melanocortin-4 receptor selective peptide towards clinical development. Our lead candidate is part of our PL2000 peptide series. In preclinical studies using diet-induced obese mice, this candidate demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration. Importantly, pharmacokinetic findings in larger animals supports the potential for once weekly or even less frequent dosing in humans. These attributes are central to our development strategy.

For patients with chronic lifelong conditions such as hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome, a therapy that combines robust efficacy with convenient dosing and improved tolerability could represent or does represent important advancements in the field. Our lipidated peptide approach is designed to extend drug exposure and pharmacological activity, potentially enabling sustained therapeutic benefits with fewer injections. We are currently advancing the IND-enabling preclinical and manufacturing activities necessary to support our first-in-human study. We are targeting initiation of a Phase I single, multiple and multiple ascending dose study in the first half of calendar 2027 with initial clinical data target to occur in the second half of the year. This represents an important upcoming milestone for Palatin.

The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics of our next-generation lipidated peptide in humans and also include measurements of skin pigmentation, body weight, body mass index and effects on appetite. We believe the combination of melanocortin-4 receptor selectivity, sustained activity and demonstrated preclinical efficacy makes this an especially promising development candidate. We also continue to advance our non-lipidated PL1000 peptide series, including formulation strategies intended to support long-acting administration. Together, these programs provide multiple opportunities to develop differentiated peptide-based melanocortin-4 receptor therapies. Beyond our injectable peptide programs, we see significant opportunity in oral melanocortin-4 receptor therapies. Oral administration has obvious appeal for patients and caregivers managing chronic conditions.

We believe our extensive medicinal chemistry and pharmacology experience provides a strong foundation for addressing the challenges associated with earlier melanocortin-4 receptor oral programs. Our next-generation oral small molecule program builds on the knowledge gained from our prior development candidate, PL-7737 and our broader melanocortin-4 receptor discovery efforts. We have now identified compounds with improved potency and MCR4 selectivity compared with earlier candidates together with favorable oral bioavailability and preclinical evaluations. We continue to optimize these candidates with a particular emphasis on potency, receptor selectivity, gastrointestinal tolerability and suitability for chronic administration.

Our target is to advance a selected candidate into IND-enabling development in the first half of 2027 and to initiate a Phase I clinical study in the second half of calendar 2027. Additionally, our oral peptide agonist approach has made significant progress. We have developed selective melanocortin-4 receptor agonists with gastrointestinal stability and oral bioavailability that supports further development. Although this effort is earlier in development, it provides a compelling opportunity to develop novel orally delivered MCR4 peptide therapeutics and expands the range of technologies and therapeutic profiles that we can pursue. Our goal is to develop a portfolio of best-in-class melanocortin-4 receptor therapies rather than depending on a single molecule or delivery approach.

There is growing interest in novel melanocortin-4 receptor-based therapeutics and Palatin is very well positioned to take advantage of this interest and deliver best-in-class therapeutics. First, we have extensive experience with the melanocortin receptor system, including the development of bremelanotide, the first melanocortin-4 receptor compound approved by the FDA. Second, we have generated a substantial body of proprietary medicinal chemistry, pharmacology and clinical development knowledge that informs the design of our next-generation compounds. Third, our development strategy is focused on specific clinical limitations that have become apparent with existing and emerging therapies. And fourth, we are pursuing multiple complementary approaches, including lipidated injectable peptides, non-lipidated peptide formulations, oral small molecules and oral peptide approaches.

We believe these capabilities position us to develop highly differentiated therapies in a market where therapeutic mechanism has been well validated and where meaningful unmet medical need remains. In addition to our internal melanocortin-4 receptor development programs, we continue to realize value from our broader melanocortin portfolio. Our collaboration with Boehringer Ingelheim for retinal diseases provides ongoing research reimbursement and the potential for additional development, regulatory and commercial milestone, payments and royalties. Our agreement with Altanispac Labs transfers future development responsibility for PL9643 in dry eye disease while preserving potential future economics for Palatin. We also continue to evaluate partnering opportunities for our additional clinical stage and proof-of-concept programs.

These arrangements reflect an important element of our overall strategy, maintaining our proprietary focus on melanocortin-4 receptor obesity development while utilizing collaborations and licensing mechanisms to advance other assets. Before turning the call over to questions, I want to emphasize one final point. We believe the melanocortin-4 receptor system represents one of the most compelling validated mechanisms for treating rare neuroendocrine obesity disorders. The opportunity now is to build better medicines around this mechanism. Our next-generation programs are specifically designed to do that. We have demonstrated compelling preclinical characteristics, including potent melanocortin-4 receptor agonism without melanocortin-1 receptor activation and tested compounds and sustained activity with our lead lipidated peptide.

We are advancing these programs toward human clinical evaluation with important milestones targeted throughout 2027. With that, I will turn the call over to questions.

Operator: [Operator Instructions] First question from Scott Henry with AGP.

Scott Henry: I'll start with sort of the big picture. We've seen a lot of interest around the MC4R pathway in peptides. Certainly, reports of interest in Rhythm Pharmaceuticals from AstraZeneca. We've got Gilead and PepStar. What does this activity suggest to you about the pathway? I mean, it certainly seems like interest is heating up. And how do you believe Palatin is positioned within this environment?

Carl Spana: Thanks, Scott. I think that I think it's self-evident, right? It shows you that there is a growing interest in this mechanism, on both the peptide front and the small molecule front. We're seeing a lot more interest coming inbound. A lot more companies are approaching us. So we're quite excited about where the mechanism sits with the growing interest outside of not just specialty pharma, but large pharma as evidenced by AstraZeneca. In general, overall, peptides are becoming a lot more interesting in the sense that the ability to lipidated peptides to increase -- to reduce the number of injections, so going from either one or more injections per day to one injection per week or even longer.

And the fact that many of these lipidated peptides can be stabilized for oral delivery really is opening up the field. So large pharma is yet, again, revisiting peptides as a validated therapeutic approach. And again this is all based on -- off of the success that's been seen with the GLP-1s. So overall, I think this is a very big positive for the melanocortin field and peptides in general, the interest that AstraZeneca and others are showing in the target. So -- and I think from a Palatin perspective, we're very well positioned. We are a peptide company. We've developed lots of peptide agonists and antagonists.

We have lots of core technologies for understanding how to lipidate these peptides correctly so that they maintain selectivity and reduce number of injections and good potency. And now we've been opening -- we've been able to essentially open up the aspect of giving oral delivery with these peptides as well. We've been able to generate both lipidated and non-lipidated peptides that are extremely stable in gastrointestinal fluid and intestinal fluid as well, and they're showing oral bioavailability in the range that allows them to be -- for oral delivery. So we feel we're really well positioned across the board.

Scott Henry: Okay. And a natural extension to that question, as investors look at Rhythm as sort of a comp for Palatin, how would you compare and contrast what you're doing versus what Rhythm is working on?

Carl Spana: I mean, Rhythm has been very successful in pioneering the use of MCR4 agonist for treating rare and orphan indications. So I mean -- and so they've really opened up the field. And as I said on the call, it's now about getting the best compounds. It's really developing better -- either peptides, small molecules to come into that marketplace that provide better attributes and differentiated attributes for patients. We believe on the peptide front that lipidated approach is superior to using polymers. Polymer proteins do work, but they have their limitations, whereas the lipidated peptides don't. You can draw the direct analogy from what was done with the GLP-1s.

They started out as once or twice a day injectables, they went to polymers and then they went to lipidation and lipidated drugs really have taken off. They're just easier to use, better the formulate easier to use, you can titrate and you have a lot more flexibility. So we believe lipidated peptide that reduces MCR1 activity and maintains high MCR4 potency is really going to be a superior product to other peptide approaches that are out there. On the small molecule front, the goal here is -- there's one out there. It's okay. It's the first generation.

I think that the type of compounds that we're working on and others may be working on are going to be superior with regards to selectivity, potency and overall drug-like characteristics that are going to allow them just to be dosed in an easier format and a wider dosing range to potentially drive more efficacy. So I think across the board, we're very differentiated from what Rhythm has done. But with that being said, they're out there. They're the first and they're pioneering these markets. And our intent is to come along with superior and differentiated products to be -- and be competitive. And I feel that we're there with the compounds that we're bringing forward.

Scott Henry: Okay. Great. Perhaps I'll give Steve a chance to speak. Steve, given the heightened interest around the sector, does that make you feel much more confident? I know financing is an important need. It doesn't look like the warrants are going to come into play just quite yet. So do you think this background enhances the outlook for financing in the near term?

Steve Wills: Absolutely. First off, thanks for the question, Scott there. The -- we absolutely have to recognize the importance of securing additional capital to support the next stages of our development programs. And that's really the -- notwithstanding the advancement of the MCR4 obesity program, that's our key corporate priority. We've operated more than 25 years. We're 100% successful regarding accessing the capital markets, also executing strategic transactions. And that's been done through multiple development cycles and market landscapes. As Carl highlighted, we have a compelling portfolio of next-generation MC4R programs that we believe are differentiated from, albeit the commercial programs out there and the development -- the programs under development.

We, of course, are actively evaluating financing alternatives, public, private equity, and we're looking at strategic opportunities there. It's -- the interest is significantly greater over the last several months than it's ever been at Palatin and the MCR4 landscape is the primary factor in that regard. But since Nostradamus has not returned my calls, we cannot provide assurances regarding the timing or the terms of the transaction, but we're focused on advancing the programs and pursuing the resources necessary to achieve our objectives.

Scott Henry: Okay. Great. Just a couple of minor questions for you, Carl, just follow-ups. First, on the peptide front, you're working on PL1000, which is the non-lipidated; and PL2000, the lipidated. My understanding is the PL2000, the lipidated, is in the lead between those two compounds. And that it appears you're going to take that one into the clinic first. Is that correct?

Carl Spana: That's correct. That's correct. We -- again, we have both what we call simple peptides, which are essentially these are our cyclized peptides that are -- very true, they look like bremelanotide, they would look like setmelanotide. These would be daily injectable type of products. And they'd have to be formulated in polymers or other types of technologies if you wanted to extended delivery. So we're going forward with lipidated. Lipidated, we think, is a superior product and a superior approach to long-term delivery of peptides.

Scott Henry: Okay. And the other question I just had was the oral small molecule compound, it seems like that time line sort of shifted up a little bit with data now expected in the first half '28. Is that correct? Or perhaps I was just being conservative expecting it in second half of '28?

Steve Wills: I'll jump in on time lines there, Scott. It's Steve. The -- no, we haven't changed that. The oral small molecule program and also the oral peptide program is tracking approximately 2 quarters behind the lipidated peptide program. So with the first half target for the lipidated peptide starting the Phase I and data by the end of second half of 2027, just reverse that for the oral small molecule and/or the oral peptide. It should be starting in the second half of '27 with data in the first half of calendar 2028.

Operator: Next question from Joe Pantginis with H.C. Wainwright.

Joshua Korsen: This is Josh on for Joe. So I had a few questions on the obesity week data. So you had some nice selectivity for MCR4 over MC1R. So I'm just curious your thoughts on this in relation to hyperpigmentation and kind of your confidence on how this is going to translate into patients.

Carl Spana: Sure. On -- the goal is to eliminate or much as possible MCR1 activity so that you can avoid hyperpigmentation. So in treating these conditions that we're talking about, these are chronic conditions, they're lifelong treatments. And so having the best profile is one that allows patients to stay on the longest and hyperpigmentation can be a side effect of having MCR1 activity that a number of patients don't necessarily want to experience. So being able to have the high degree of selectivity that we have.

And again, when we talk about selectivity in a couple of different ways, and I don't want to get too technical, but the most important way we think about it is really reducing the activity of your compounds against the receptor. And that's a little bit different -- that's a little bit different than what other people are doing. So we're pretty confident that we've achieved that. And as we go into the clinic, we do expect to see diminished or no pigmentation. But again, until we get to the clinic, you're not going to know. The models for -- the animal models for predicting hyperpigmentation are -- they're not that well validated. So we do them, we run them.

But I think overall, you got to go on your selectivity and your activity profile and get in the clinic.

Joshua Korsen: Okay. And you also had some early blood pressure effect. So I'm just curious what additional work that you're thinking of doing to further establish this cardiovascular profile?

Carl Spana: Sure. So I mean the cardiovascular profile is obviously -- cardiovascular safety for any drug, including melanocortin-4 agonist is important. There are some legacy issues around potential cardiovascular effects with MCR4s that we don't have in our compound. So we'll continue to evaluate their effects on blood pressure and on rhythm throughout the -- rhythm effects throughout the tox program. So you'll do that in specific studies that will look at blood pressure and EG tracing as well as in your overall 7-day, 28-day tox and longer-term tox studies. So there's nothing unique here. It's the type of stuff that you would do for all -- any drug going through development.

We'll make sure that when we go into the clinic that we do -- have the appropriate methodologies for evaluating blood pressure so that when we come out of the SAD/MAD studies, we expect to have a clean profile.

Joshua Korsen: Great. Definitely excited to see the first-in-human studies get going.

Operator: Next question from Dev Prasad with Lucid.

Dev Prasad: A quick one on the progress of -- towards the Phase I. Can you help what are the remaining steps from now to initiating the Phase I of lead lipidated peptide?

Carl Spana: Sure. A lot of the -- so if you think about the toxicology program in, in vitro, so non-animal studies and animal studies, majority of the in vitro studies have been completed. And we're getting ready to start the 28-day study in both rat and dogs, and that's really the gating item when that's done, when those reports [ are in ], we'll be able to file.

In conjunction with that, we have, of course, the ongoing CMC requirements for stability and so on and so forth and making sure that we have both the required documentation around the API or the drug itself as well as the drug product, and those are all on track to be in place to file in the second quarter of next year.

Dev Prasad: Great. And can you talk about R&D expenses moving forward? Because we see you have quite substantial expense on the September quarter?

Carl Spana: That's over to Steve.

Steve Wills: Sure. I'll take this one. So the increase in R&D spending, that's obviously directly related to the advancement of our priority development programs and particularly the IND-enabling activities of our lead lipidated peptide and the continued optimization of our small molecule and oral peptide candidates. We view this as an important investment in advancing our programs towards the clinical development. As we move closer to initiating the Phase I studies next year, certain development expenses will naturally increase, particularly those associated with manufacturing, toxicology, regulatory activities and the clinical trial preparation. At the same time, we do maintain considerable flexibility in managing the timing and pace of the expenditures.

Capital allocation strategy is focused on the programs we believe offer the greatest potential, which obviously is our MC4R obesity programs. And that means prioritizing the lead long-acting peptide and the oral MCR -- MC4R programs while leveraging partnerships to advance the other assets. And we do believe this disciplined approach allows us to concentrate our resources on the opportunities with the greatest potential to create shareholder value.

Operator: Next question from Yale Jen with Laidlaw.

Yale Jen: Carl, you're talking about the lipidated peptide potentially can be used orally. Could you elaborate a little bit more on that? And as well as was there any examples of drug already developed from the lipidated peptide to oral drug?

Carl Spana: Sure. I mean the most -- largest one, obviously, is semaglutide, which is -- was originally developed, obviously, as Ozempic. And then -- it was then developed as an oral formulation. So that's the Wegovy pill. So Wegovy pill is essentially semaglutide just formulated for oral delivery. And from our perspective, that's -- one of the things that lipidated -- having lipidated peptide approach does do for you, it does open that door to be able to do that. Simple peptides have relatively short half-life. So even if they -- even if you get them orally bioavailable in 5%, 6%, 7% range, they're going to be chewed up relatively rapidly.

But lipidated peptides when they're absorbed, they're immediately bound to albumin, so they're protected and have a long half-life, so you can build up to a therapeutic dose relatively over a week or so of dosing. So it's a well-validated approach now based on the GLP-1s. And there are a lot of number of companies that are pursuing this type of approach. I mean, a large one being -- Protagonist is a large one that has lots of oral peptide approaches and you can look at their portfolio and how they do things.

But -- one of the key things for these peptides is that not only do that be orally bioavailable, they really have to have long -- prolonged half-lives when they're absorbed because these are not drugs that -- these are not absorbed at 70% or 80%. These are 3%, 4%, 5% oral bioavailability. But because they're lipidated and they accumulate, you can get to a therapeutic dose with them.

Yale Jen: Just a sidetrack. Does all the GLP-1 or GLP the subcu one or in the lipidated form? Or -- is that the case?

Carl Spana: That's my understanding. My understanding is that if there are peptides, they're lipidated. There are certainly small molecules, traditional oral small molecules like Oforgepron, which is the Lilly product that's approved. And there are a number of smaller molecules in development. But they haven't done as well as -- Oforgepron has not done nearly as well as the Wegovy pill in the sense because -- the Wegovy pill is essentially semaglutide essentially just delivered orally. So it's the exact peptide. So -- but most of them, they need to be lipidated.

Yale Jen: Okay. Great. Maybe a question in terms of the Phase I study you're going to start in next year. Do you think there is not enough time for the study -- and when you show the data of the study that the hyperpigmentation might emerge in patients or any other biomarkers to suggest that you will be able to sort of diminish that event?

Carl Spana: So hyperpigmentation through MCR1, if you have it, you're going to see it almost within the first one to two doses. It's a very rapid effect. If you are activating MCR1 melanocytes, you will see skin darkening fairly quickly. So MAD study of 28 days is more than sufficient to see if you have significant MCR1 activity and hyperpigmentation.

Yale Jen: So that -- should that be the case that will be a strong indication that the selectivity has did its work in terms of...

Carl Spana: If the 28-day study is clean for hyperpigmentation, you will not have hyperpigmentation. [indiscernible] melanocyte, your skin turns over once a month. So you won't see anything. If you're clean on that study, you're clean.

Yale Jen: Sounds good. Sounds good. Maybe a last question for Steve. We noticed that for last year, Boehringer Ingelheim has different sort of lumpy revenue -- larger sum of the revenue occurred. Do you anticipate this pattern may happen later this year or in fiscal '27, I should say, that will potentially offset some of the need for bigger financing or whatnot?

Steve Wills: The -- are you referencing the, say, the BI -- Boehringer Ingelheim funds that came in over the last...

Yale Jen: Yes.

Steve Wills: The -- it's -- we don't for competitive reasons and confidentiality reasons, we're not announcing the anticipated milestones or the timing other than to say we did receive approximately $10 million since August of 2025. The program is advancing, progressing well. Great partnership. We love the BI folk. I think they love the Palatin folk. And as we advance the program, there will be additional milestones.

Yale Jen: Okay. Great. That's very helpful. Again, best of luck for all the progress. I mean, you guys certainly setting potentially a gold mine. Hopefully, you can harvest that later.

Operator: We have no further questions on the line. I will turn the call back over to Dr. Carl Spana for closing remarks.

Carl Spana: I'd like to thank everyone for participating on our quarterly conference call. I'd like to thank the analysts for their insightful questions. And we really are excited here. We've got a lot going on, and we've made a tremendous progress, and we've got a great team focused on delivering. So we're really excited and look forward to continue to update on our success and our progress. So thank you, everyone. Have a great day, and we'll keep you guys updated as we make progress.

Operator: Thank you. This does conclude today's conference call. You may disconnect your phone lines at this time, and have a wonderful day. Thank you for your participation.

Should you buy stock in Palatin Technologies right now?

Before you buy stock in Palatin Technologies, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palatin Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,870? | Mitrade AUGold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
Author  Mitrade Team
13 hours ago
Gold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
placeholder
Nvidia faces its biggest earnings test yet — why Silicon Valley billionaires want Jensen Huang backNvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
Author  Mark Garro
18 hours ago
Nvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
placeholder
Berkshire Hathaway's Only New Q3 Position Is a Company Few Investors RecognizeBerkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
Author  Beincrypto
19 hours ago
Berkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
placeholder
Stocks, Gold, and Asia Bleed $2.2 Trillion: Top 5 Factors That Triggered the CrashGlobal markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
Author  Beincrypto
19 hours ago
Global markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
placeholder
Tom Lee Sees No Cracks in the AI Trade Despite Nasdaq's 12% DropTom Lee, head of research at Fundstrat Global Advisors, says the artificial intelligence (AI) trade remains structurally intact. The tech-heavy Nasdaq Composite had fallen nearly 12% from its Oct. 6 r
Author  Beincrypto
19 hours ago
Tom Lee, head of research at Fundstrat Global Advisors, says the artificial intelligence (AI) trade remains structurally intact. The tech-heavy Nasdaq Composite had fallen nearly 12% from its Oct. 6 r
goTop
quote